REG - Polarean Imaging PLC - First Xenon Hyperpolariser in Asia

Polarean ImagingAnnouncement

25/11/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251125:nRSY8133Ia&default-theme=true

RNS Number : 8133I  Polarean Imaging PLC  25 November 2025

Polarean Imaging Plc

("Polarean" or the "Company")

 

First Polarean Xenon Hyperpolariser to be installed in Asia

Collaboration with Philips and Sumtage to bring Xenon MRI technology to Taiwan

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging
technology leader in functional Magnetic Resonance Imaging ("MRI") of the
lungs, announces that the National Taiwan University Hospital ("NTUH") has
entered into an agreement for a Xenon MRI research system in Taiwan through
Polarean's strategic partner, Philips (Philips Medical Systems Nederland
B.V.).

 

NTUH is widely recognised as Taiwan's leading academic medical centre, with a
strong track record in clinical research and advanced patient care. The order
will be supported by Polarean's newly appointed Taiwanese distributor
(https://www.londonstockexchange.com/news-article/POLX/taiwanese-distributor-agreement-with-sumtage/16880465)
, Sumtage Enterprise Company Limited ("Sumtage"), who will assist in the
installation and training at NTUH, and work collaboratively with Polarean on
the steps required to secure regulatory approval and reimbursement in Taiwan.

 

This milestone represents Polarean's first entry into Asia and an important
step in building the foundations for future adoption of Xenon MRI in the
region.

 

Christopher von Jako, Ph.D., CEO of Polarean, said: "This first Xenon MRI
system in Taiwan, supported by Philips and Sumtage, marks an important
milestone in our international strategy. The National Taiwan University
Hospital is the country's premier academic medical centre, and this order
highlights the recognition of Xenon MRI's potential in lung health. Together
with Sumtage, we will focus on ensuring successful installation and training
at NTUH while also advancing the regulatory and reimbursement pathways needed
for broader adoption in Taiwan."

 

Hui-Lin Su, General Manager of Sumtage, said: "We are excited to partner with
Polarean to bring this groundbreaking Xenon MRI technology to Taiwan. Our goal
is to support hospitals like NTUH with not only the technology itself, but
also the training and long-term support required for success. We look forward
to working with Polarean to secure regulatory approval and reimbursement so
that physicians and patients across Taiwan can benefit from this innovation."

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018.

 

For more information, visit www.xenoview.net (http://www.xenoview.net) .

 

Enquiries:

 Polarean Imaging plc                                                  www.polarean.com / www.polarean-ir.com (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer                  Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                                       +44 (0)20 7710 7600
 Nicholas Moore / Fred Walsh / Brough Ransom  / Ben Good

 Walbrook PR              Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
                          (mailto:polarean@walbrookpr.com)
 Anna Dunphy/ Paul McManus / Marcus Ulker            Mob: +44 (0)7876741001 / +44 (0) 7980541893 / +44 (0)7867984 082

 

 

 

About Polarean

 

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com/) .

 

XENOVIEW IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 6 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.

 

Please see full prescribing information at www.XENOVIEW.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBZLLLEFLBFBX



            Copyright 2019 Regulatory News Service, all rights reserved